# GRI Bio, Inc.

**GRI**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001824293

# None

**No letter**

5 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $8.7M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, thin data, degenerate inputs<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Jan 30, 2026<br>263 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026 |
| **Last close** | $1.45<br>2026-10-19; market equity $3.2M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Jan 30, 2026*

We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. Our product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. The active pharmaceutical ingredient in GRI-0621, tazarotene, is a synthetic retinoid acid receptor-beta and gamma selective agonist.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 17.3** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (24.6%) | (6.6%) | 17.3 | 812 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 64.4** | | | | | | |
| Twelve-month failure probability | not computable | 0.06% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (21.86) | (0.30) | 74.6 | 757 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 3.25x | 2.96x | 54.2 | 840 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 49.8** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 1* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 4* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | 182.8% | 2.1% | 0.6 | 705 | 2025-12-31 | |
| Net share issuance, one year | 7,601.6% | 2.5% | 99.1 | 634 | 2026-01-29 | |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 7601.6% |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-10-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (96.7%) | 8.0% | 0 |
| Distance from 52-week high | (97.7%) | (31.9%) | 1 |
| EBIT to enterprise value | not computable | (1.6%) | |
| Free cash flow yield | (321.4%) | (1.0%) | 3 |
| Book value to price | 3.24 | 0.28 | 98 |
| Sales to price | 0.00 | 0.31 | 0 |
| Composite equity issuance, five years | not computable | 20.3% | |
| Relative strength against the sector, log excess return | (3.61) | (0.13) | 0 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $10.9M |
| Operating cash flow, four quarters | -$10.4M |
| Months of runway | 12.6 |
| Days since last periodic filing | 67 (10-Q received Aug 14, 2026) |
| Median daily dollar volume, 63 sessions | $86,913 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$12.0M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$10.2M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 3 | assets | us-gaap:Assets | $8.7M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 4 | assets | us-gaap:Assets | $5.7M | 2024-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 5 | current assets | us-gaap:AssetsCurrent | $8.6M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $2.6M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$51.7M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$12.0M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 9 | book equity | us-gaap:StockholdersEquity | $6.0M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 10 | liabilities | us-gaap:Liabilities | $2.7M | 2025-12-31 | 2026-01-30 | 10-K | 26-000033 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $0 | 2021-12-31 | 2022-02-14 | 10-K | 22-000004 |
| 12 | assets | us-gaap:Assets | $3.0M | 2023-12-31 | 2025-03-14 | 10-K | 25-000050 |
| 13 | assets | us-gaap:Assets | $383,000 | 2022-12-31 | 2024-03-28 | 10-K | 24-000033 |
| 14 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 1,445,029 | 2026-01-29 | 2026-01-30 | 10-K | 26-000033 |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 525,358 | 2025-03-11 | 2025-03-14 | 10-K | 25-000050 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.